Skip to site menu Skip to page content

Data Insights

Filter search results

By Company Name

No Filter Selected

By Disease Name

No Filter Selected

By Drug Name

No Filter Selected

By Themes
Showing 20 results out of 25

Company profileChongqing Precision Biotech

Access the most comprehensive report about Chongqing Precision Biotech available on the market

  • Gain competitive edge
  • Enhance your sales strategy
  • Gain competitive edge
  • Enhance your sales strategy
GlobalData

Buy Now
Data Insights

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia by Chongqing Precision Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Chongqing Precision Biotech...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD123 For Relapsed And Refractory Acute Myeloid Leukemia in Relapsed Acute Myeloid Leukemia

Data Insights

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia by Chongqing Precision Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Gene Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Chongqing Precision Biotech...

Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD123 For Relapsed And Refractory Acute Myeloid Leukemia in Refractory Acute Myeloid Leukemia